| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CMM3; PSK-J3 |
| WB Predicted band size | 34 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human CDK4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CDK4抗体的3-4篇参考文献的简要列举：
---
1. **文献名称**：*CDK4/6 inhibition in breast cancer: mechanisms and clinical implications*
**作者**：Goel S, DeCristo MJ, Watt AC, et al.
**摘要**：该研究探讨了CDK4/6抑制剂(如帕博西尼)在雌激素受体阳性(ER+)乳腺癌中的作用机制，通过使用CDK4抗体检测肿瘤细胞中CDK4蛋白的表达水平，揭示其对细胞周期调控的影响及耐药性产生的潜在途径。
---
2. **文献名称**：*Palbociclib and letrozole in advanced breast cancer*
**作者**：Finn RS, Crown JP, Lang I, et al.
**摘要**：这项临床试验(PALOMA-1)评估了CDK4/6抑制剂帕博西尼联合来曲唑治疗ER+/HER2-晚期乳腺癌的疗效。研究利用CDK4抗体对患者肿瘤组织进行免疫组化分析，发现高CDK4表达与治疗响应率相关。
---
3. **文献名称**：*Targeting CDK4/6 in cancer therapy: from in vitro models to clinical application*
**作者**：Asghar U, Witkiewicz AK, Turner NC, et al.
**摘要**：文章综述了CDK4/6抑制剂的临床前研究进展，重点通过CDK4抗体在体外模型中验证其对Rb阳性肿瘤的增殖抑制作用，并讨论了生物标志物开发中抗体的应用潜力。
---
4. **文献名称**：*CDK4 amplification is predictive of resistance to CDK4/6 inhibitors in neuroblastoma*
**作者**：Otto T, Horn S, Brockmann M, et al.
**摘要**：该研究发现成神经细胞瘤中CDK4基因扩增与CDK4/6抑制剂耐药性相关。通过CDK4抗体的免疫印迹和免疫荧光实验，证实扩增导致蛋白过表达，为靶向治疗提供新见解。
---
以上文献涵盖了CDK4抗体在基础研究、临床试验及耐药机制中的典型应用场景。
CDK4 (Cyclin-Dependent Kinase 4) is a serine/threonine kinase critical for regulating the cell cycle transition from the G1 to S phase. It forms complexes with D-type cyclins (e.g., cyclin D1) to phosphorylate and inactivate the retinoblastoma (Rb) protein, releasing E2F transcription factors that drive DNA replication and cell proliferation. Dysregulation of CDK4. often due to gene amplification, overexpression, or mutations, is implicated in uncontrolled cell division and tumorigenesis. Aberrant CDK4 activity is observed in various cancers, including melanoma, breast cancer, liposarcoma, and glioblastoma, making it a key therapeutic target.
CDK4 antibodies are essential tools in both research and diagnostics. In research, they are used to detect CDK4 expression levels (via Western blot, immunohistochemistry, or flow cytometry) and study its interaction with cyclins or inhibitors. Clinically, CDK4 antibodies aid in cancer biomarker profiling to guide targeted therapies. For example, CDK4/6 inhibitors like palbociclib and ribociclib, which block kinase activity, are FDA-approved for hormone receptor-positive breast cancer. Additionally, CDK4-specific monoclonal antibodies are under investigation for therapeutic applications, aiming to selectively inhibit hyperactive CDK4 in tumors while sparing normal cells.
The development and validation of high-affinity, specific CDK4 antibodies remain crucial for advancing mechanistic studies, improving diagnostic accuracy, and optimizing therapeutic strategies in precision oncology. Ongoing research continues to explore their potential in combination therapies and resistance mechanisms.
×
